FDA Expands Risankizumab Label in Psoriatic Disease
The FDA expanded the indications for risankizumab (Skyrizi) in plaque psoriasis and psoriatic arthritis to include treatment of children 6 years and older, AbbVie announced. An interleukin (IL)-23 antagonist, risankizumab…








